IO Biotech Secures $57.5M to Accelerate Next-Generation Immune-Oncology Innovations

IO Biotech, a groundbreaking clinical-stage biopharmaceutical company, has just raised $57,500,000 in funding to advance its mission of revolutionizing cancer therapeutics. Leveraging its novel T-win® platform, the company is at the forefront of developing immune-modulatory, off-the-shelf cancer vaccines that uniquely activate T cells to target both tumor cells and the immune-suppressive components of the tumor microenvironment. With the raised capital, IO Biotech aims to accelerate the advancement of its lead candidate, Cylembio, which is currently progressing through clinical trials. The funding will also bolster the further development of its robust pipeline of preclinical candidates, ensuring a continued commitment to innovation and the expansion of its therapeutic portfolio. Headquartered in Copenhagen, Denmark, with a key US presence in New York, New York, IO Biotech benefits from a dynamic global footprint that blends European innovation with American market expertise. The company’s success is underpinned by its experienced management team, which brings deep expertise in the field of immune-oncology, as well as a world-class advisory board committed to scientific excellence and industry-leading insights. This infusion of capital not only validates IO Biotech’s strategic vision but also underscores the confidence that investors have in its potential to transform cancer treatment paradigms. As the company moves forward, it will leverage this significant financial backing to expedite clinical studies, expand research initiatives, and ultimately bring innovative therapies to patients in need. This funding milestone marks a pivotal step in IO Biotech’s journey to redefine cancer care and offers renewed hope for improved therapeutic outcomes in a field with an immense unmet need.